ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rituximab"

  • Abstract Number: 1232 • ACR Convergence 2021

    Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients

    Matthew Turk1, Candice Low2, Carl Orr3, Richard Conway4, Kieran Murray5, Ursula Fearon6 and Douglas Veale7, 1St. Vincents University Hospital, Dublin, Ireland, 2St. Vincent's University Hospital, Dublin, Ireland, 3St Vincent's Hospital, Dublin, Ireland, 4St. James's University Hospital, Dublin, Ireland, 5Saint Vincent's University Hospital, Dublin, Ireland, 6Trinity College Dublin, Dublin, Ireland, 7University College Dublin, Dublin, Ireland

    Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…
  • Abstract Number: 1445 • ACR Convergence 2021

    Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)

    Namrata Singh1, Chen Hu2, Vithal Madhira2, Kate Fitzgerald2, Timothy Bergquist3, Kayte Anderson2, Amy Olex4, Rena Patel5 and Jasvinder Singh6, 1University of Washington, Bellevue, WA, 2Johns Hopkins, Baltimore, MD, 3Sage Bionetworks, Seattle, WA, 4Virginia Commonwealth University, Richmond, VA, 5UW, Seattle, WA, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…
  • Abstract Number: 1562 • ACR Convergence 2021

    B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab

    Sarah Jinich, Deanna Jannat-Khah and Robert Spiera, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…
  • Abstract Number: 0005 • ACR Convergence 2021

    Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome

    Mathijs Broeren1, Giulia Balzaretti2, Jing Wang3, Patricia Groenen1, Barbera van Schaik4, Tim Chataway3, Charlotte Kaffa1, Sander Bervoets1, Konnie Hebeda1, Gergana Bounova5, Ger Pruijn1, Tom Gordon3, Niek De Vries6 and Rogier Thurlings7, 1Radboud University Medical Center, Nijmegen, Netherlands, 2Amsterdam, Netherlands, 3Flinders University, Adelaide, Australia, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Enpicom BV, Den Bosch, Netherlands, 6Amsterdam UMC, Amsterdam, Netherlands, 7Radboud University Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Sjögren's syndrome (SjS) involves chronic inflammation of exocrine glands that can be complicated by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). We…
  • Abstract Number: 0321 • ACR Convergence 2021

    Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation

    André van Maurik1, David Gardner2, Saba Nayar2, Charlotte Smith2, Kenneth Clark1, Prafull Mistry1, Rajesh Punwaney3, David Roth3, Robert Henderson1, Xavier Mariette4 and Francesca Barone2, 1GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 2University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
  • Abstract Number: 0416 • ACR Convergence 2021

    Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis

    Jason Springer1 and Ryan Funk2, 1Vanderbilt University Medical Center, Franklin, TN, 2University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…
  • Abstract Number: 0649 • ACR Convergence 2021

    Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention

    Daniel Magliulo1, Stefanie Wade2 and Vasileios Kyttaris3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3BIDMC, Boston, MA

    Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
  • Abstract Number: 0964 • ACR Convergence 2021

    Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases

    Samuel Bitoun1, Julien Henry2, Christelle Vauloup Fellous3, Raphaele Seror4, Lina Mouna3, Candie Joly5, Delphine Desjardins5, Marie Bitu5, Roger Le Grand6, Anne-Marie Roque Afonso3 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Le Plessis Robinson, France, 3AP–HP, Hôpital Paul-Brousse, Department of Virology, University Paris Saclay, INSERM U1193,, Villejuif, France, 4Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184, FHU CARE FHU CARE, Le kremlin Bicetre, France, 5Paris-Saclay University, Inserm UMR 1184, FHU CARE, CEA, Le Kremlin Bicêtre, France, 6UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, Fontenay Aux Roses, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…
  • Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium

    Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

    Mei-Sing Ong1, Deborah Rothman 2 and Marc Natter 3, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Massachusetts General Hospital, Springfield, 3Boston Children's Hospital, Boston

    Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
  • Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium

    Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

    Linda Wagner-Weiner 1, Vidya Sivaraman 2, Karen James 3, Eric Yen 4, Kathleen O'Neil 5, Dana Gerstbacher 6, Ann Marie Szymanski7, Kimberly Morishita 8 and David Cabral 9 for the CARRA investigators, 1University of Chicago, Chicago, Illinois, 2Division of Rheumatology, Nationwide Children's Hospital, Bexley, 3University of Utah, 84113, Utah, 4UCLA, Los Angeles, California, 5University of Indiana School of Medicine, Indianapolis, Indiana, 6Stanford University School of Medicine, Palo Alto, California, 7Tampa, Florida, 8University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, 9BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

    Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
  • Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium

    Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease

    Alexis Wilsey1, Heather Van Mater 2 and Laura Cannon 2, 1Durham, 2Duke University, Durham

    Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…
  • Abstract Number: 143 • 2020 Pediatric Rheumatology Symposium

    Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease

    Laura Cannon 1, Stephanie Johannes1 and Jeffrey Dvergsten 2, 1Duke University, Durham, 2Duke University Hospital, Hillsborough

    Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and Autoimmune Encephallitis (AE) arise due to dysregulation of the immune system and a…
  • Abstract Number: 1034 • 2019 ACR/ARP Annual Meeting

    Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus

    Carlos Perez-Sanchez1, Irene Cecchi 2, Laura Pérez-Sanchez 3, Alejandra Patiño-Trives 4, Nuria Barbarroja 5, Maria Luque-Tevar 4, Alejandro Ibañez-Costa 4, Ivan Arias de la Rosa 6, Maria del Carmen Abalos-Aguilera 4, Rafaela Ortega 4, Alejandro Escudero 7, Massimo Radin 2, Savino Sciascia 8, Mª Ángeles Aguirre-Zamorano 7, Eduardo Collantes-Estevez 6 and Chary Lopez-Pedrera 4, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2University of Turin, Turin, Italy, 3MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, 6University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 8Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

    Background/Purpose: Recent studies have highlighted the potential role of microRNAs (miRNAs) as diagnostic and prognostic biomarkers in Systemic Lupus Erythematosus (SLE). While Rituximab (RTX) represents…
  • Abstract Number: 2131 • 2019 ACR/ARP Annual Meeting

    Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases

    Cristóbal Pavez Perales1, Jorge Juan Fragio Gil 1, Roxana Gonzalez Mazarío 1, José Ivorra Cortés 1, Elena Grau García 1, Cristina Alcañiz Escandell 1, Inmaculada Chalmeta Verdejo 1, Marta de la Rubia Navarro 1, Luis González Puig 1, Isabel Martínez Cordellat 1, Rosa Negueroles Albuixech 1, José Eloy Oller Rodríguez 2, Francisco Miguel Ortiz-Sanjuán 1, Elvira Vicens Bernabeu 1, Carmen Nájera Herranz 1, Inés Cánovas Olmos 1, Samuel Leal Rodriguez 1 and José Andrés Román Ivorra 1, 1Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 2Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain

    Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody inducing B cell depletion, is used as therapy for diverse systemic autoimmune diseases (SAIDs), but is associated with adverse events…
  • Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting

    Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

    Stephen McDonald1, Eoghan McCarthy 2, Aysun Aksoy 3, Ben Parker 4 and Ian Bruce 5, 1University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University Foundation Trust, The Kellgren Centre, Manchester, United Kingdom, Belfast, Northern Ireland, United Kingdom, 2Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, 3Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, 4University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, 5University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom

    Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology